Carbon Health announced today that it acquired Steady Health and its platform for using continuous glucose monitoring to personalize diabetes care. San Francisco–based Carbon Health said in a news release that the acquisition accelerates its rollout of a new primary care model designed to integrate its clinic footprint with virtual and hardware-enabled capabilities to create […]
Patient Monitoring
Dexcom touts CGM studies, shares data on next-gen G7
Dexcom (NSDQ:DXCM) today shared results from two studies of continuous glucose monitors, including its next-generation G7 CGM. San Diego-based Dexcom presented the studies during the 14th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). The first study, the Mobile study, published in JAMA, observed 175 ethnically and socioeconomically diverse adults (30 years old […]
Study shows CGMs better at controlling blood sugar in type 2 diabetes
Kaiser Permanente is touting a study demonstrating that using continuous glucose monitors offers better blood sugar control for patients with type 2 diabetes. The study found that patients with insulin-treated type 2 diabetes using continuous glucose monitors (CGMs) typically had better blood sugar control and fewer visits to the emergency room for hypoglycemia. The study […]
DarioHealth touts research on digital therapeutics for diabetes patients
DarioHealth (NSDQ:DRIO) announced today that recently published research supports its digital therapeutic platform for type 2 diabetes. New York-based DarioHealth published a new study through a letter to the editor in the Journal of Diabetes Science and Technology, according to a news release. The study observed participants using DarioHealth’s digital therapeutics for diabetes management, monitoring […]
Medtronic wins CE mark for smart insulin pen, Guardian 4 sensor
Medtronic (NYSE:MDT) announced today that it received CE mark approvals for its InPen smart insulin pen and its Guardian 4 sensor. Fridley, Minn.-based Medtronic’s new European approvals cover expanded functionality of the InPen for multiple daily injections (MDI), along with approval for the Guardian 4 sensor that requires no fingersticks for calibration or diabetes treatment […]
Senseonics stock up on Street-beating Q1
Senseonics (NYSE:SENS) shares rose today on first-quarter results that beat the consensus forecast. The Germantown, Md.-based diabetes management technology developer posted losses of -$249.5 million, or -68¢ per share, on sales of $2.8 million for the three months ended March 31, 2021, registering a massive bottom-line slide from losses of -$42.6 million this time one […]
Lilly partners with four companies on insulin pen tech
Eli Lilly (NYSE:LLY) today announced deals with four companies whose diabetes management tech will work with Lilly’s latest insulin pen. The Tempo Pen is a modified version of Lilly’s existing prefilled, disposable insulin pen to which the Tempo Smart Button — in late-stage development – attaches. Through these new agreements, the Tempo Smart Button will […]
DarioHealth partners with MediOrbis on virtual diabetes care platform
DarioHealth (NSDQ:DRIO) announced that it launched a new virtual care initiative with MediOrbis to improve virtual care for diabetes. New York-based DarioHealth’s collaboration with MediOrbis is slated to offer eligible Medicare members with diabetes a convenient method for virtual care that includes MediOrbis’ telehealth offerings and DarioHealth’s AI-powered remote patient monitoring, according to a news […]
Virta Health raises $133M Series E for diabetes reversal tech
Virta Health announced today that it raised $133 million in a Series E equity financing round led by Tiger Global. San Francisco-based Virta said in a news release that the funds will accelerate its efforts to drive the adoption of its telehealth-based diabetes reversal treatment that aims to reverse the chronic disease while removing the […]
CeQur raises $115M for wearable insulin delivery device
CeQur announced today that it closed an oversubscribed equity financing round with proceeds of $115 million. Lucerne, Switzerland/Marlborough, Mass.–based CeQur said in a news release that it plans to use the funds to advance the commercial plans for the CeQur Simplicity wearable insulin delivery device. The company’s plans include market development, a phased commercial launch […]